- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PD-L1 negative
- ER negative
- PR negative
- EGFR positive
- KRAS positive
- EGFR negative
- BRAF positive
- p16 positive
- ALK negative
- CD20 positive
- BRCA1 positive
- HLA-A positive
- BRCA2 positive
- ALK positive
- MET positive
- CD19 positive
- IDH positive
- HLA positive
- BRAF negative
- MYC positive
- IDH negative
- ROS1 negative
- MET negative
- RET positive
- p16 negative
- HLA negative
- HPV positive
- HR positive
- ROS1 positive
- TP53 positive
- MSI-H positive
- PIK3CA positive
- NRAS positive
- dMMR positive
- BCL2 positive
- PALB2 positive
- RB1 positive
- BRCA positive
- HLA-A negative
- RAS positive
- HPV negative
- BCL6 positive
- MSS positive
- NF1 positive
- ANA positive
- CCND1 positive
- CD5 positive
- KRAS negative
- NTRK positive
- RB1 negative
- RET negative
- FLT3 positive
- TP53 negative
- BRCA1 negative
- MMR negative
- PTEN positive
- BRCA2 negative
- FGFR2 positive
- MGMT negative
- MMR positive
- RAS negative
- ctDNA positive
- ARID1A positive
- BCR-ABL1 positive
- MSI-H negative
- anti-dsDNA positive
- dMMR negative
- CD19 negative
- CFTR positive
- HbSS positive
- KIT positive
- MGMT positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- NTRK negative
- PMS2 positive
- ATM positive
- CD30 positive
- CD4 positive
- CLDN18.2 positive
- Ex19del positive
- HBsAg positive
- HRAS positive
- L858R positive
- MSI negative
- NRAS negative
- PD-1 positive
- SMN1 positive
- p53 positive
- pMMR positive
- t(11;14) positive
- BRCA negative
- BRIP1 positive
- CD20 negative
- CD3 positive
- CHEK2 positive
- Del(17p) positive
- HBV DNA negative
- HPV16 positive
- HR negative
- Ki-67 positive
- MSI positive
- MSS negative
- NF2 positive
- NTRK1 positive
- PD-1 negative
- RAD51 positive
- RF positive
- ABCA4 positive
- APC positive
- CD8 positive
- CDK12 positive
- COL7A1 positive
- FANCA positive
- FGFR3 positive
- FLT3 negative
- FMR1 positive
- GPC3 positive
- GRN positive
- HBV DNA positive
- MDM2 positive
- RAF positive
- SMN2 positive
- TROP2 positive
- TTR positive
- anti-Smith positive
- t(11;14)(q13;q32) positive
- APOL1 positive
- ASXL1 positive
- BARD1 positive
- CD123 positive
- CD22 positive
- DLL3 positive
- DMD positive
- EPCAM positive
- ER or PR positive
- HBsAg negative
- KMT2A positive
- Ki67 positive
- MECP2 positive
- NPM1 positive
- NY-ESO-1 positive
- PTEN negative
- Ph positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- RAD51C positive
- RAD51D positive
- SMARCB1 negative
- SMARCB1 positive
- STK11 positive
- T790M positive
- TERT positive
- TMB positive
- TROP2 negative
- dsDNA positive
- t(14;16) positive
- t(4;14) positive
- 1p negative
- AKT1 positive
- APP positive
- BAP1 positive
- BCR-ABL positive
- C5 positive
- C9orf72 positive
- CD23 positive
- CD30 negative
- CD33 positive
- CD34 positive
- CD4 count positive
- CHEK1 positive
- CTNNB1 positive
- DMPK positive
- DNMT3A positive
- EBV DNA positive
- EBV positive
- FANCL positive
- FGFR positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- HBcAb negative
- HEXA positive
- HEXB positive
- HRD positive
- HTT positive
- IAA positive
- JAK2 positive
- Ki-67 negative
- L861Q positive
- MAGE-A4 positive
- MTAP positive
- PDGFRA positive
- PIK3CA negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- ARD-101
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Radiation for 4-6 weeks
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
10497 trials
1
2
3
…50